



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

In re Application of: Thim et al.

AUG 2 8 2002

Serial No.:09/528,644

Group Art Unit: 1647

TECH CENTER 1600/2900

Filed: March 20, 2000

Examiner: David Romeo

Confirmation No: 5698

For: Human Spasmolytic Polypeptide in Glycosylated Form

490 495/02

FILING OF CONTINUED PROSECUTION APPLICATION (CPA) UNDER 37 C.F.R. §1.53(d)

Commissioner for Patents Box CPA Washington, DC 20231

This is a request for filing a continuation application under 37 CFR 1.53(d) of prior application number 09/528,644 filed on March 20, 2000, entitled Human Spasmolytic Polypeptide in Glycosylated Form.

- 1. [] Please enter the Amendment(s) filed on _____ under 37 CFR 1.116 in the prior nonprovisional application.
- 2. [X] A Preliminary Amendment is enclosed.
- 3. [] This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53(d)(4). Delete the following inventors(s) named in the prior nonprovisional application:

- 4. [X] An Information Disclosure Statement is enclosed.
- 5. [X] The filing fee is calculated as follows:

Basic Fee: \$740.00Total Claims: $10 - 20 = 0 \times 18 = 0.00

Independent Claims: $1 - 3 = 0 \times 84 =$ \$0.00 Total Fee: \$740.00

6. [X] Applicant hereby petitions for an extension of time under 37 CFR 1.136 for two (2) months. If an additional extension of time is required, please

08/27/2002 AUONDAF1 00000068 141447 09528644

01 FC:131 740-0

740.00 CH

08/27/2002 AUONDAF1 00000068 141447 09528644

02 FC:116

400.00 CH

consider this a petition therefor. The required extension fee is estimated to be \$400.00.

- Please charge the required fee, estimated to be \$1,140.00, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.
- 8. [] _____ is included.

Respectfully submitted,

Date: August 19, 2002

Richard W. Bork, Reg. No. 36,459 Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10174-6401 (212) 867-0123

23650
PATENT TRADEMARK OFFICE